New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

Shares of Eli Lilly finished Thursday 3% higher despite an earnings report that showed sales of its blockbuster GLP-1 weight-loss drugs, Zepbound and Mounjaro, missed estimates for the second ...

Moreover, the stigma surrounding obesity disproportionately affects lower-income individuals, who are often blamed for their ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...

Novo Nordisk expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs. The Danish ...